# A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors

> **NCT01131104** · — · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 345 (actual)

## Conditions studied

- Nonarteritic Anterior Ischemic Optic Neuropathy

## Interventions

- **DRUG:** PDE5 Inhibitors

## Key facts

- **NCT ID:** NCT01131104
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 345 (ACTUAL)
- **Last updated:** 2018-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01131104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01131104, "A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01131104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*